Radiation boosts immunotherapy in lung cancer? new trial aims to find out

NCT ID NCT07353476

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at people with stage III non-small cell lung cancer who had chemotherapy plus immunotherapy before surgery, and still had cancer in their lymph nodes after the tumor was removed. Half will get standard immunotherapy alone after surgery, and the other half will get immunotherapy plus radiation to the lymph nodes. The goal is to see if the combination helps keep the cancer from coming back longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radiation therapy and an anti-PD-1 immunotherapy drug
What this could lead to: If it works, this could point toward a more effective treatment plan for lung cancer patients who still have cancer in their lymph nodes after surgery and chemotherapy.
What could go wrong: This is a small, early-phase study with only 38 participants, so results may not apply to everyone. Adding radiation also raises risks of side effects like lung inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) POST SURGICAL

More trials for these conditions

Other studies related to the condition(s) this trial covers.